Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v5-FR | Version v2-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2022-12-05 | 2022-10-03 |
| Drug Identification Number | 02139510 | 02139510 |
| Brand name | SODIUM CHLORIDE INJECTION, USP | SODIUM CHLORIDE INJECTION, USP |
| Common or Proper name | SODIUM CHLORIDE INJECTION, USP | SODIUM CHLORIDE INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | SODIUM CHLORIDE | SODIUM CHLORIDE |
| Strength(s) | 234MG | 234MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 200mL | 200mL |
| ATC code | B05XA | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2022-10-03 | 2022-10-03 |
| Actual start date | 2022-10-03 | 2022-10-03 |
| Estimated end date | Unknown | Unknown |
| Actual end date | 2022-11-30 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Due to the early availability of our 100 mL format, effective October 3, 2022 allocations for our Sodium Chloride Injection, USP 4mEq/mL Maxivial® 200 mL have been reduced. Contract customers are allocated 100% of historical monthly demand of the 200 mL only. | Due to the early availability of our 100 mL format, effective October 3, 2022 allocations for our Sodium Chloride Injection, USP 4mEq/mL Maxivial® 200 mL have been reduced. Contract customers are allocated 100% of historical monthly demand of the 200 mL only. |
| Health Canada comments |